Literature DB >> 34033893

Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.

Albrecht Stenzinger1, Anders Edsjö2, Carolin Ploeger3, Mikaela Friedman4, Stefan Fröhling5, Valtteri Wirta6, Thomas Seufferlein7, Johan Botling8, Justus Duyster9, Michael Akhras6, Robert Thimme10, Thoas Fioretos11, Michael Bitzer12, Lucia Cavelier13, Peter Schirmacher3, Nisar Malek12, Richard Rosenquist14.   

Abstract

Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Clinical trials; Molecular profiling; Personalized medicine; Precision medicine

Mesh:

Year:  2021        PMID: 34033893     DOI: 10.1016/j.semcancer.2021.05.026

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  4 in total

1.  [Histopathological evaluation of nonalcoholic fatty liver disease : Automated evaluation of liver biopsies].

Authors:  Nada Abedin; Andrea Tannapfel; Peter J Wild; Iris Tischoff
Journal:  Pathologe       Date:  2022-02-16       Impact factor: 1.011

Review 2.  [Artificial intelligence: a solution for the lack of pathologists?]

Authors:  Philipp Jurmeister; Klaus-Robert Müller; Frederick Klauschen
Journal:  Pathologe       Date:  2022-04-11       Impact factor: 1.011

3.  Intratumoral and peritumoral CT-based radiomics strategy reveals distinct subtypes of non-small-cell lung cancer.

Authors:  Xing Tang; Haolin Huang; Peng Du; Lijuan Wang; Hong Yin; Xiaopan Xu
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-17       Impact factor: 4.322

4.  Multidisciplinary Effort to Drive Precision-Medicine for the Future.

Authors:  Dewei Kong; Haojie Yu; Xueling Sim; Kevin White; E Shyong Tai; Markus Wenk; Adrian Kee Keong Teo
Journal:  Front Digit Health       Date:  2022-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.